131 related articles for article (PubMed ID: 34419957)
1. Glucose deprivation enhances resistance to paclitaxel via ELAVL2/4-mediated modification of glycolysis in ovarian cancer cells.
Park GB; Jeong JY; Choi S; Yoon YS; Kim D
Anticancer Drugs; 2022 Jan; 33(1):e370-e380. PubMed ID: 34419957
[TBL] [Abstract][Full Text] [Related]
2. PGAM1 Promotes Glycolytic Metabolism and Paclitaxel Resistance via Pyruvic Acid Production in Ovarian Cancer Cells.
Feng Y; Zhang X; Zhang S; Xu S; Chen X; Zhou C; Xi Y; Xie X; Lu W
Front Biosci (Landmark Ed); 2022 Sep; 27(9):262. PubMed ID: 36224008
[TBL] [Abstract][Full Text] [Related]
3. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
4. Glycolysis is essential for chemoresistance induced by transient receptor potential channel C5 in colorectal cancer.
Wang T; Ning K; Sun X; Zhang C; Jin LF; Hua D
BMC Cancer; 2018 Feb; 18(1):207. PubMed ID: 29463225
[TBL] [Abstract][Full Text] [Related]
5. A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models.
Xintaropoulou C; Ward C; Wise A; Marston H; Turnbull A; Langdon SP
Oncotarget; 2015 Sep; 6(28):25677-95. PubMed ID: 26259240
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
7. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.
Sullivan EJ; Kurtoglu M; Brenneman R; Liu H; Lampidis TJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):417-27. PubMed ID: 24352250
[TBL] [Abstract][Full Text] [Related]
8. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.
Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T
Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607
[TBL] [Abstract][Full Text] [Related]
9. CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.
Tang XH; Li H; Zheng XS; Lu MS; An Y; Zhang XL
Cancer Med; 2019 Oct; 8(14):6426-6436. PubMed ID: 31490008
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.
Aldonza MB; Hong JY; Lee SK
Exp Mol Med; 2017 Jan; 49(1):e286. PubMed ID: 28104912
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
[TBL] [Abstract][Full Text] [Related]
12. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M; Ouyang Q; Goldberg MS; Amiji MM
Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
[TBL] [Abstract][Full Text] [Related]
13. RNA-Binding Proteins HuB, HuC, and HuD are Distinctly Regulated in Dorsal Root Ganglia Neurons from STZ-Sensitive Compared to STZ-Resistant Diabetic Mice.
Mustăciosu CC; Banciu A; Rusu CM; Banciu DD; Savu D; Radu M; Radu BM
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013625
[TBL] [Abstract][Full Text] [Related]
14. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
[TBL] [Abstract][Full Text] [Related]
15. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA (LncRNA) SNHG7/ Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2) involves in the malignant events of ovarian cancer cells with paclitaxel resistant.
Zhang J; Zhang R; Ye Y
Bioengineered; 2021 Dec; 12(2):10541-10552. PubMed ID: 34709112
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract][Full Text] [Related]
19. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]